NetworkNewsBreaks Archive - Page 1936 of 1966

ThursdayDec 15, 2016 1:16 pm

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Shows Promise as the Dark Horse of RCM Market

Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP) is one of many progressive firms vying to enter the U.S. ambulatory EHR/RCM (revenue cycle management) market, which is valued at more than $13 billion. “Currently, there are at least 1,500 companies offering RCM services in this highly competitive arena. None commands more than 10 percent of market share. The largest, athenahealth (NASDAQ: ATHN), has about 7% of the market. With annual revenues that are likely to exceed $1.0 billion this year, the market value of its equity is close to 4x revenues. Its stock currently trades at around $93.00. This makes…

WednesdayDec 14, 2016 2:47 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 14, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: BLTO 136.00% – News: Initiates development of free bingo app SIRC 105.88%– News: Reports record revenue for October, November 2016 BBLS 18.14% – News: Commences drilling program; Reports oil reserves 273% increase QEGY 14.94% – News: Issues shareholder update MRNA 14.80% – News: New Board of Directors member named CIIX 13.95% – News: Entered wholesale agreement with a CBD health brand, Enables retail of CBD products to target Asian health market DMPI 12.07% –…

WednesdayDec 14, 2016 2:04 pm

NetworkNewsBreaks – BrainStorm Cell Therapeutics (NASDAQ: BCLI) Trades Higher Following Positive Data from Phase 2 Study of NurOwn®

Shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) are up 23% following the announcement that new, positive data from the company's phase 2 study of NurOwn® in ALS were presented by lead investigator Dr. James Berry at the 27th International Symposium on ALS/MND in Dublin, Ireland. The data showed disease symptoms were essentially halted for the period of the treatment effect. This effect was even more prominent in the pre-specified subgroup that was defined in order to exclude subjects whose disease was progressing slowly. "Importantly, there is evidence that NurOwn® may be halting disease progression or improving symptoms in some patients. The CSF biomarker profiles were…

WednesdayDec 14, 2016 2:00 pm

NetworkNewsBreaks – Advanced Environmental Petroleum Producers (AEPP) Obtains Technical Evaluation Agreement; Moves forward with Pilot Plant

Advanced Environmental Petroleum Producers (OTCQB: AEPP) this morning said it had received clearance to manufacture and install the full Pilot Plant from its exclusive technology supplier Pointsource Processing (PSP) for the extraction of gas and oil after receiving the acceptance of its Technical Evaluation Agreement (TEA) for Block 19 Certificate. "AEPP can now instruct Chapman Petroleum Engineers from Calgary Alberta Canada to proceed on site to complete the 51-101 Petroleum Reserve Report for Block 19," Nigel Bosworth, AEPP's chief technology officer, stated in the news release. To view the full press release, visit: http://nnw.fm/gTy1C About Advanced Environmental Petroleum Producers, Inc.…

WednesdayDec 14, 2016 1:58 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Receives FDA Approval for MACI®; Shares Soar

Shares of Vericel Corp. (NASDAQ: VCEL) are up more than 60% mid-day after the company broke news of the approval of MACI® (autologous cultured chondrocytes on porcine collagen membrane) by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. "We believe that the introduction of MACI, along with investments to expand our commercial organization…

TuesdayDec 13, 2016 3:17 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 13, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: IDDR: 135.45% – News: Contracted by NRECA to provide its IDDriven 2.0 Identity Software CBLY 63.33%– News: American Fiber Optics Group subsidiary secures financing for $34M manufacturing facility QFOR 56.72 % – News: Moving on momentum from recent CEO, COO appointments VMRI: 48.47% – News: Orders five Transition BASE Systems from ALTI UAS EWLL 39.13% – News: CEO was interviewed on ABC Channel 7 News in Los Angeles ENRT 33.74% – News: Initiates bench…

TuesdayDec 13, 2016 3:01 pm

NetworkNewsBreaks – Revance Therapeutics, Inc. (RVNC) Reports Positive Preliminary from Phase 2 Cervical Dystonia Trial

Shares of Revance Therapeutics (NASDAQ: RVNC) are ticking higher after the biotech company reported positive interim results from its U.S. phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults, a movement disorder of the neck. Final results are expected in the first half of 2017. “ … I am particularly encouraged that in this trial RT002 exhibited a safety profile at least as good as currently marketed neurotoxins. Furthermore, with a sustained median duration of at least 24 weeks, there is a possibility that patients will require injections only two times…

TuesdayDec 13, 2016 2:51 pm

NetworkNewsBreaks – Organovo (ONVO) Presenting 3D Bioprinted Human Liver Tissue Data at TERMIS-Americas Meeting

Organovo Holdings, Inc. (NASDAQ: ONVO) is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models at the ongoing TERMIS-Americas Meeting in San Diego. Organovo intends to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its therapeutic liver tissue in three to five years. “Our preclinical data show rapid vascularization and tissue engraftment, and evidence of function and durability of our 3D bioprinted human liver tissue over several weeks. Most importantly, we see evidence of stable production of key human liver…

TuesdayDec 13, 2016 2:45 pm

NetworkNewsBreaks – Soligenix, Inc. (SNGX) Prices $5,277,000 Public Offering, Debuts on Nasdaq

Soligenix (NASDAQ: SNGX, SNGXW) shares are 34% lower on its first day of uplisting to the Nasdaq Capital Market. The late-stage biopharmaceutical company this morning priced an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16 – for gross proceeds of approximately $5,277,200. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events; are exercisable immediately; and will…

TuesdayDec 13, 2016 2:44 pm

NetworkNewsBreaks – Achaogen, Inc. (AKAO) Proposes Common Stock Public Offering, Proceeds to Advance Plazomicin

Achaogen (NASDAQ: AKAO) has initiated an underwritten public offering of up to 5,750,000 shares of its common stock, all of which are offered by the company. Additionally, Achaogen expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The company said it intends to use the net proceeds to fund the ongoing development and preparation for potential commercialization of its lead candidate plazomicin, for which the company yesterday announced positive results in phase 3 cUTI and CRE clinical…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks